Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
In vivo clinical effectiveness of artificial intelligence screening for acute coronary syndrome: testing real-world performance
0
Zitationen
9
Autoren
2026
Jahr
Abstract
Objective Many predictive models are being developed, but few are deployed in clinical care. Hence, model performance within live real-world care is often not known. We trained a predictive model (in vitro) to (1) estimate patients’ risk of acute coronary syndrome (ACS) on arrival to the emergency department (ED) and (2) identify those with highest risk for ST-segment myocardial infarction (STEMI) to receive an early ECG. We embedded this model into clinical care as clinical decision support (CDS) and using dynamic real-world data (in vivo), ran a silent pilot. We aimed to test the CDS’s replication of the original model’s screening performance and compare to standard of care screening by human staff. Methods and analysis The CDS prospectively assessed each patient arriving in the ED between November 2023 and April 2024. It calculated each patient’s risk for ACS, recorded a decision about whether the patient should receive an early ECG and was programmed to not exceed the total number of ECGs performed in human practice, approximately 33%. We used raw agreement and Cohen’s Kappa to compare the screening decisions of the in vivo CDS and original in vitro model. We then measured sensitivity for ACS, our primary outcome, and specificity, which we compared between the CDS’s and human screening decisions. Results 32 346 visits were seen in the ED and processed by the CDS. 1.0% had ACS and 0.1% STEMI. Raw agreement between the CDS and original model was 96.8%, and Kappa was 91.2% (95% CI 90.7% to 91.8%). Sensitivity for ACS was 81.7% (95% CI 77.1% to 85.8%) in CDS versus 80.2% (95% CI 75.4% to 84.4%) observed in humans. Specificity for ACS was 67.3% (95% CI 66.8% to 67.9%) versus 67.4% (95% CI 66.9 to 67.9%), respectively. Conclusion We found very good raw agreement and Kappa scores between the CDS and original model. Sensitivity and specificity between the CDS and human practice did not differ. This suggests that, when CDS is deployed independent of human decision-making, we can expect very high, although not perfect, performance replication. These differences need to be quantified and considered to estimate the real-world impact of models before deployment.
Ähnliche Arbeiten
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
2017 · 9.589 Zit.
ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary
2004 · 8.365 Zit.
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 · 8.275 Zit.
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
1996 · 7.477 Zit.
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
1998 · 7.047 Zit.